GSK
743 hedge funds and large institutions have $7.87B invested in GSK in 2022 Q3 according to their latest regulatory filings, with 132 funds opening new positions, 244 increasing their positions, 273 reducing their positions, and 274 closing their positions.
102% more call options, than puts
Call options by funds: $433M | Put options by funds: $214M
0.26% less ownership
Funds ownership: 13.39% → 13.13% (-0.26%)
11% less repeat investments, than reductions
Existing positions increased: 244 | Existing positions reduced: 273
18% less funds holding
Funds holding: 902 → 743 (-159)
20% less capital inflows, than outflows
Capital inflows: $1.81B | Capital outflows: $2.26B
24% less funds holding in top 10
Funds holding in top 10: 17 → 13 (-4)
52% less first-time investments, than exits
New positions opened: 132 | Existing positions closed: 274
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$223M |
| 2 |
Two Sigma Advisers
New York
|
+$159M |
| 3 |
Armistice Capital
New York
|
+$136M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$101M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$100M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parallax Volatility Advisers
San Francisco,
California
|
-$484M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$175M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$159M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$141M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$132M |
GSK Hedge Fund Activity: Q3 2022 in Review
743 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q3 2022, worth a combined $7.87B — down 50% from $15.7B a quarter earlier.
Sellers outnumbered buyers: 274 funds closed out of GSK and 132 opened new positions — a net loss of 142 holders — while 273 trimmed existing stakes and 244 added.
The largest buyer was Two Sigma Investments, adding an estimated $223M. The largest seller was Parallax Volatility Advisers, cutting an estimated $484M.
- 743 institutional investors held GSK (GSK) as of Q3 2022, down from 902 in Q2 2022.
- Funds reported $7.87B of GSK stock for Q3 2022, down 50% quarter-over-quarter.
- 132 funds opened new GSK positions in Q3 2022 and 274 closed out, a net change of -142 holders.
- The largest GSK buyer in Q3 2022 was Two Sigma Investments, an estimated $223M added.
- The largest GSK seller in Q3 2022 was Parallax Volatility Advisers, an estimated $484M sold.
Based on aggregated 13F filings for Q3 2022.